Try Alerts Free   |   Login
Health Care › Services Home Health Care Services

AHCO Price Correlated With Financials For AdaptHealth

Free historical financial statements for AdaptHealth Corp.. See how revenue, income, cash flow, and balance sheet financials have changed over 9 quarters since 2020. Compare with AHCO stock chart to see long term trends.

AHCO Stock Compared to Quarterly

AHCO Income Statement

Revenue, Net:706203000
Revenue Per Share:5.2588
Cost of Goods & Services Sold:597122000
Selling, General & Admin Expense:41444000
Total Operating Expenses:654651000
Operating Income:51552000
Income Taxes:5603000
Net Income:42230000
Earnings Per Share, Basic:0.29
Shares Outstanding, Basic Avg:134289067

AHCO Cash Flow

Operating Activities Net Income:
Depreciation, Depletion & Amortization:77030000
Change in Accounts Receiveable:9481000
Net Cash from Operations:66451000
Net Cash from Operations Per Share:0.4948
Net Cash from Financing Activities:-16552000
Property, Plant & Equipment Purchases:77166000
Purchases of Businesses, Net of Cash:2932000
Net Cash from Investing Activities:-80098000
Net Change in Cash & Equivalents:-30199000

AHCO Balance Sheet

Cash and Cash Equivalents:119428000
Accounts Receivable, Net:369898000
Total Current Assets:614988000
Property, Plant & Equipment, Net:424764000
Total Assets:5204341000
Accounts Payable:212820000
Current Portion of Long-Term Debt:20000000
Total Short-Term Liabilities:443555000
Long Term Debt, Non-Current Portion:2179730000
Total Liabilities:3083715000

Insider Trading

SEC Form 4
SkyKnight Aero Holdings II, LLC   Director
100,200 sh at $17
SkyKnight Capital, L.P.   Director
100,000 sh at $17
SkyKnight Capital Fund II, L.P.   Director
100,000 sh at $17
SkyKnight Capital Fund II, L.P.   Director
13,922 sh at $17
SkyKnight Capital Fund II, L.P.   Director
35,091 sh at $18
SkyKnight Capital Fund II, L.P.   Director
209,300 sh at $17
SkyKnight Capital Fund II, L.P.   Director
21,632 sh at $16
SkyKnight Capital Fund II, L.P.   Director
180,154 sh at $16
WOLF DALE B   Director
7,000 sh at $25
(1)          General Information AdaptHealth Corp. and subsidiaries (AdaptHealth or the Company), a Delaware Corporation, is a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment (HME), medical supplies, and related services. AdaptHealth focuses primarily on providing (i) sleep therapy equipment, supplies and related services (including CPAP and bi PAP services) to individuals suffering from obstructive sleep apnea (OSA), (ii) medical devices and supplies to patients for the treatment of diabetes (including continuous glucose monitors (CGM) and insulin pumps), (iii) home medical equipment to patients discharged from acute care and other facilities, (iv) oxygen and related chronic therapy services in the home, and (v) other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy and nutritional supply needs. AdaptHealth services beneficiaries of Medicare, Medicaid and commercial insurance payors. ​ The interim consolidated financial statements are unaudited, but reflect all normal recurring adjustments that are, in the opinion of management, necessary to fairly present the information set forth herein. The interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. Interim results are not necessarily indicative of the results for a full year. ​ There have been no material changes in the Company’s significant accounting policies as compared to the significant accounting policies described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. ​ (a)          Basis of Presentation The interim consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP). In the opinion of management, the interim consolidated financial statements include all necessary adjustments for a fair presentation of the financial position and results of operations for the periods presented. (b)         Basis of Consolidation The accompanying interim consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. (c)          Concentration of Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents and trade accounts receivable. The Company maintains its cash in bank deposit accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk on cash and cash equivalents. (d)          Accounting Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and reported amounts of revenues and expenses during the reporting period. Management bases these estimates and assumptions upon historical experience, existing and known circumstances, authoritative accounting pronouncements and other factors that management believes to be reasonable. Significant areas requiring the use of management estimates relate to revenue recognition and the valuation of accounts receivable (implicit price concession), income taxes, contingent consideration, equity-based compensation, interest rate swaps, warrant liability and long-lived assets, including goodwill and identifiable intangible assets. Actual results could differ from those estimates. (e)          Valuation of Goodwill The Co

Data imported from AdaptHealth Corp. SEC filings. Check original filings before making any investment decision.